{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RET-altered+Papillary+Thyroid+Cancer",
    "query": {
      "condition": "RET-altered Papillary Thyroid Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:31:55.479Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04759911",
      "title": "Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Thyroid Gland Neoplasm",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Thyroid Gland Anaplastic Carcinoma",
        "Thyroid Gland Medullary Carcinoma",
        "Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-02-26",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-21T22:31:55.479Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04759911"
    },
    {
      "nct_id": "NCT03899792",
      "title": "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Medullary Thyroid Cancer",
        "Infantile Myofibromatosis",
        "Infantile Fibrosarcoma",
        "Papillary Thyroid Cancer",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 36,
      "start_date": "2019-06-13",
      "completion_date": "2029-05",
      "has_results": true,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-05-21T22:31:55.479Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03899792"
    },
    {
      "nct_id": "NCT03037385",
      "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "RET-altered Non Small Cell Lung Cancer",
        "Medullary Thyroid Cancer",
        "RET-altered Papillary Thyroid Cancer",
        "RET-altered Colon Cancer",
        "RET-altered Solid Tumors",
        "Lung Neoplasm",
        "Carcinoma, Non-Small-Cell Lung",
        "Thyroid Diseases",
        "Thyroid Neoplasm",
        "Thyroid Cancer, Papillary",
        "Carcinoma, Neuroendocrine",
        "Respiratory Tract Neoplasms",
        "Thoracic Neoplasms",
        "Neoplasms by Site",
        "Neoplasms",
        "Lung Diseases",
        "Respiratory Tract Disease",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Endocrine System Diseases",
        "Endocrine Gland Neoplasm",
        "Head and Neck Neoplasms",
        "Adenocarcinoma, Papillary",
        "Adenocarcinoma",
        "Carcinoma",
        "Neoplasms, Glandular and Epithelial",
        "Neoplasms by Histologic Type",
        "Neuroendocrine Tumors",
        "Neuroectodermal Tumors",
        "Neoplasms, Germ Cell and Embryonal",
        "Neoplasms, Nerve Tissue",
        "Colonic Neoplasms",
        "Colorectal Neoplasms",
        "Intestinal Neoplasms",
        "Gastrointestinal Neoplasms",
        "Digestive System Neoplasm",
        "Digestive System Disease",
        "Gastrointestinal Disease",
        "Colonic Diseases",
        "Intestinal Disease"
      ],
      "interventions": [
        {
          "name": "pralsetinib (BLU-667)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2017-03-17",
      "completion_date": "2024-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-05-21T22:31:55.479Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03037385"
    }
  ]
}